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sharp health deterioration with age. Nevertheless, moderate health problems are
considered as acceptable in advanced ages. These findings intend to support com-
pliance research and health gain valuations.
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OBJECTIVES: Sleep issues have been reported by patients with rheumatoid arthri-
tis (RA) and recently recommended as a clinical trial endpoint. The objective of this
study was to conduct a quantitative validation of the sleep disturbance and sleep
adequacy subscales of the 1-week recall Medical Outcomes Study Sleep Scale
(MOS-SS) in patients with RA. METHODS: Participants with self-reported RA were
recruited via newspaper or online advertisements in two regions of the US. Partic-
ipants completed measures in-person, then completed a one-week retest via mail.
Internal consistency of the MOS-SS subscales was evaluated using Cronbach’s ;
test-retest reliability was assessed using Intraclass Correlation Coefficient (ICC).
Pearson’s correlation coefficient was calculated to assess convergent validity of
MOS-SS 1-week subscales with a Sleep Numeric Rating Scale (NRS). Known-groups
validity was assessed using ANOVA to compare MOS-SS mean subscale scores with
self-reported RA severity (mild, moderate, severe) and general health (very good,
good, fair, poor). RESULTS: Participants (N50) were 76% female, 72% White, mean
age (SD) 49.4 (13.2) years and mean disease duration (SD) 13.7 (12.0) years. Cron-
bach’s  for sleep disturbance and adequacy subscales were 0.73 and 0.71, respec-
tively. Mean sleep disturbance and adequacy subscale scores were 47.1 and 34.0 at
baseline, 47.3 and 32.0 at 1-week follow-up (ICC0.78 and 0.75), respectively. Cor-
relations of the sleep disturbance and adequacy subscales with the Sleep NRS were
r0.43 (p0.002) and r0.45 (p0.001), respectively. Mean sleep disturbance and
adequacy subscale scores across RA severity and health status groups trended as
hypothesized but were not significantly different. CONCLUSIONS: The MOS-SS
sleep disturbance and sleep adequacy subscales demonstrated good internal con-
sistency and test-retest reliability, modest convergent validity, and trended but did
not significantly discriminate based on RA severity or general health. Further psy-
chometric analysis in a larger sample of RA patients is needed to determine if these
subscales could be useful in clinical trials.
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OBJECTIVES: Fatigue has been reported by patients as an important symptom of
rheumatoid arthritis (RA) and recommended for measurement in clinical trials.
The objective was to evaluate the validity of, ‘WORST level of fatigue (weariness,
tiredness) during the past 24 hours,’ item of the Brief Fatigue Inventory (BFI Q3) in
a sample of US patients with self-reported RA. METHODS: 50 adults with RA were
recruited to complete questionnaires at baseline and one week later. Internal con-
sistency reliability of the BFI fatigue severity subscale (questions 1-3) was evalu-
ated using Cronbach’s . BFI Q3 was assessed using Intraclass Correlation Coeffi-
cient (ICC) for test-retest reliability; Pearson’s correlation coefficient for convergent
validity with BFI fatigue severity subscale and Multidimensional Assessment of
Fatigue (MAF) global score; and analysis of variance for known-groups discriminant
validity with self-reported RA severity (mild, moderate, severe) and general health
(very good, good, fair, poor). RESULTS: Participants were 76% female, 72% Cauca-
sian, mean age (SD) 49.4(13.2) years and mean disease duration 13.7(12.0) years.
Mean BFI Q3 score was 7.3(1.9) at initial and 6.8 (2.3) at retest; ICC0.58. Correlation
with fatigue severity subscale and MAF were r0.79(p.001) and r.02(p.92), re-
spectively. Cronbach’s  for severity subscale 0.84. Mean BFI Q3 scores were 6.0,
7.1 and 7.8 (p.36) and poor general health were 5.6, 7.0, 7.9, and 9.0 (p.01),
respectively. CONCLUSIONS: In a small sample of patients with RA, assessment of
worst fatigue severity as measured by BFI Q3 demonstrated validity. Discrimina-
tion based on RA severity was not significant, possibly due to low study power,
however trended in the hypothesized direction. Test-retest reliability was low but
acceptable, and expected due potentially to the episodic nature of fatigue. Further
validation of the BFI Q3 in a larger sample is needed to confirm these findings that
the measure is useful in the context of RA clinical trials.
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OBJECTIVES: Osteoarthritis (OA) has significant patient and economic burden. De-
spite treatments for OA, data on treatment patterns, adequacy of pain relief, and
quality of life are limited. SORT was designed to determine the adequacy of pain
relief, and compare patterns of clinical care and patient reported outcomes (PROs)
in patients with knee OA.METHODS: SORT, a 12-month prospective, observational
study will enroll 1400 participants (across 6 countries) who use oral or topical
analgesics for knee OA symptoms. Participants visiting a primary care physician
must be  50 years old. Clinical history, medications, quality of life and resource
use are collected at baseline and months 1, 3, 6, 9 and 12. Inadequate pain relief
(IPR) was defined as an average Brief Pain Inventory pain score of “moderate or
greater pain” (score 4). This interim assessment reports data from the UK only.
RESULTS: To date, 141 participants from the UK have provided baseline data: 67%
women; median (range) age 68 years (51-90); history of diagnosed knee OA for an
average of 6 years and 68% taking oral pain medication only. Hypertension (52%)
was the most common co-morbidity. IPR was reported by 64% of the cohort at
baseline (90 of 141). Patients reporting IPR and non-IPR were similar in clinical
characteristics (p.05): BMI 31 kg/m2 (20-55), co-existing OA of the hip (16%) &
spine (29%). Participants with IPR (vs. non-IPR) differed in their rating of other PROs:
WOMAC Stiffness (mean: 127 vs. 81, p 0.01); Physical Function (969 vs. 499, p
0.01); SF-12 General Health (fair/poor 42% vs. 12%, p0.01) and satisfaction with
prescribed treatment (less than satisfied 47% vs. 28%, p 0.01). CONCLUSIONS:
With 64% of UK participants reporting IPR at baseline, SORT will provide valuable
insight into current treatment patterns and PROs for individuals with knee OA.
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OBJECTIVES: The patient perspective has become increasingly important in the
field of rheumatology research. Understanding cross-cultural experiences of RA is
helpful when designing clinical trials that include PRO measures. Qualitative data
from this study were used to compare the experiences of patients with RA in the US
and UK. METHODS: Patients with RA in the US and UK who met specific inclusion
and exclusion criteria were recruited; criteria in UK were less restrictive than in the
US. Concept elicitation interviews were conducted and interview transcripts were
analyzed with the aid of ATLAS.ti software to identify concepts and explore inter-
relationships between concepts. Data were collected and analyzed in accordance
with the US FDA’s final guidance on PRO instrument development and validation.
RESULTS:A total of 32 participants were recruited (19 in US; 13 in UK), of which the
majority were female (74% in US; 77% in UK) and White (68% in US; 77% in UK).
Mean age (SD) of the US and UK participants was 65.1 (6.9) and 47.7 (14.7), respec-
tively. Descriptions of RA in both populations were similar and included pain
(n32) and fatigue-like effects of RA (n17), which impacted daily activity and
psychological well-being. Descriptions of pain were similar in US and UK popula-
tions: “dull,” “shooting,” “nagging,” and “gnawing.” The term ”fatigue” was men-
tioned spontaneously by some (n5, 26%) of US participants, and was not men-
tioned spontaneously by any UK participants. The majority of those asked whether
fatigue was a term they would use to describe their symptom affirmed the use of
fatigue (71.4% in US and 90% in UK). CONCLUSIONS: This small, qualitative, study
identified few differences in experiences of RA in US and UK patient populations.
Qualitative research is useful for identifying whether the use of identical PRO mea-
sures is acceptable in multi-national clinical trials.
PMS61
RAPID REDUCTIONS IN FATIGUE AND SLEEP PROBLEMS AND CORRELATION
WITH IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH
ACTIVE RA TREATED WITH CERTOLIZUMAB PEGOL IN THE REALISTIC 12-WEEK
PHASE IIIB RANDOMISED CONTROLLED STUDY
Pope J1, Fleischmann R2, Dougados M3, Bingham CO4, Massarotti E5, Wollenhaupt J6,
Duncan B7, Coteur G8, Weinblatt ME5
1Univ of Western Ontario, London, ON, Canada, 2University of Texas, Dallas, TX, USA, 3Hopital
Cochin, Paris, France, 4Johns Hopkins University, Baltimore, MD, USA, 5Brigham and Women’s
Hospital, Boston, MD, USA, 6Klinikum Eilbek, Hamburg, 22081, Germany, 7UCB, Raleigh, NC,
USA, 8UCB, Brussels, Belgium
OBJECTIVES: To determine the impact of CZP on patient-reported outcomes
(PROs), including fatigue and sleep problems, among patients (pts) with active RA
who participated in the REALISTIC (RA EvALuation In Subjects receiving TNF Inhib-
itor Certolizumab pegol [CZP]) study. METHODS: A total of 1,063 eligible pts were
randomised 4:1 to CZP 400mg at Wks 0, 2 and 4 followed by 200mg every 2 wks or
placebo injection (control) every 2 wks added to current therapy. PROs included
fatigue (Fatigue Assessment Scale [FAS]), sleep quantity and quality (Sleep Problem
Index II domain, Medical Outcomes Study sleep scale [MOS-SPI]), pain (visual ana-
logue scale [VAS]), and pts global assessment of disease activity (PtGA, VAS). The %
of pts reporting minimal clinically important differences (MCIDs) was determined:
1 FAS, 6 MOS-SPI, and 10mm pain-VAS and PtGA. Correlations between PROs
and DAS28 were assessed (Pearson 
, CZP group only). NCT00717236. RESULTS:
Baseline (BL) characteristics were similar for both groups. Significant, meaningful
improvements, compared with BL, in fatigue were reported with CZP vs control
from the first time point at Wk 2 (1.1 vs 0.2; p0.001) to Wk 12 (1.3 vs 0.5;
p0.001). Sleep problems were significantly reduced with CZP vs control from
the first assessment at Wk 6 (7.6 vs 4.8; p0.05) to Wk 12 (7.6 vs 4.2;
p0.01). CZP significantly reduced pain and PtGA from Wk 2 (pain:15.3 vs2.8,
PtGA:14.7 vs2.5; p0.001). At Wk 12, more CZP pts had improvementsMCID
in FAS (56.4% vs 46.2%, p0.01), MOS-SPI (49.7% vs 42.5%, p0.058), pain (59.0%
vs 42.0%, p0.001) and PtGA (59.5% vs 42.5%, p0.001). Correlations between
PROs and DAS28 were moderate (0.3rho0.6). CONCLUSIONS: CZP was associ-
ated with clinically meaningful reductions in fatigue and sleep problems, and im-
provements in pain and PtGA, in a diverse group of RA pts reflecting those seen in
daily clinical practice.
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